tiprankstipranks
Trending News
More News >
Cibus (CBUS)
NASDAQ:CBUS
US Market
Advertisement

Cibus (CBUS) AI Stock Analysis

Compare
594 Followers

Top Page

CBUS

Cibus

(NASDAQ:CBUS)

Rating:42Neutral
Price Target:
$1.50
▲(19.05% Upside)
Cibus's overall stock score is primarily impacted by its weak financial performance and valuation, reflecting ongoing profitability challenges and negative cash flows. Technical indicators suggest bearish momentum, further weighing on the score. While the earnings call provided some positive future guidance, immediate financial and operational challenges remain significant.
Positive Factors
Cost Management
Cibus reported a reduction in operating expenses driven by management’s cost reduction efforts, which is part of a restructuring initiative aimed at focusing on core projects.
Regulatory Developments
The U.S. Department of Agriculture's designation of Cibus’ HT2 herbicide-tolerance trait in canola as not regulated could facilitate market access.
Revenue Potential
Management expects the commercialization of Cibus' sustainable ingredients and biofragrance products to generate significant revenues, with expectations of material expansion in the future.
Negative Factors
Financial Performance
Cibus announced a quarterly net loss, highlighting ongoing financial challenges despite improvements.
Investor Sentiment
Maintaining the timeline for their core gene-edited trait and sustainable ingredient opportunities is crucial, as delays could impact investor sentiment.
Workforce Changes
Cibus has continued its reduction in force, lowering headcount by 34 employees, to right-size the business.

Cibus (CBUS) vs. SPDR S&P 500 ETF (SPY)

Cibus Business Overview & Revenue Model

Company DescriptionCibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
How the Company Makes MoneyCibus generates revenue through the commercialization of its gene-edited agricultural products, which include seeds and crop traits that improve performance and resilience. The company typically licenses its technology to agricultural firms, receiving upfront fees and ongoing royalties based on product sales. Key revenue streams include partnerships with large agricultural companies, which allow Cibus to leverage their distribution networks and market access. Additionally, Cibus may benefit financially from grants and collaborations with research institutions focused on agricultural innovation.

Cibus Earnings Call Summary

Earnings Call Date:Aug 14, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in the commercialization of rice herbicide traits and biofragrance products, alongside positive regulatory developments. However, challenges include a delay in the EU regulatory process and a notable net loss. The company's strategic focus on cost reduction and capital allocation is aimed at managing cash usage effectively.
Q2-2025 Updates
Positive Updates
Progress in Rice Herbicide Tolerance Traits
Cibus's rice herbicide tolerance traits, HT1 and HT3, are progressing on schedule with potential annual royalty revenue over $200 million starting from Latin America in 2027 and the U.S. in 2028.
Biofragrance Commercialization
Biofragrance products are set to generate nominal revenues starting later this year with targeted commercial expansion ramping in 2026.
Regulatory Advances
Positive regulatory developments in multiple regions, including ongoing acceptance of gene-editing technologies and a favorable outlook in the EU, are creating a strong foundation for global marketing of Cibus's trait pipeline.
Financial Position and Cash Management
As of June 30, 2025, Cibus had $36.5 million in cash and cash equivalents, with an expectation to fund operations into Q2 2026, aided by a $27.5 million public offering.
Reduction in Operating Expenses
Research and development expenses decreased by $800,000, and selling, general, and administrative expenses decreased by $2.7 million due to cost reduction initiatives.
Regulatory Clearance for Alfalfa
The FDA completed its review of Cibus's altered lignin alfalfa trait, clearing the way for U.S. commercialization.
Negative Updates
Delay in EU Regulatory Process
The EU trialogue discussions on gene editing have been delayed beyond the initial target, with resolution now expected within the next 6 months.
Net Loss
Cibus reported a net loss of $26.6 million for the second quarter, slightly reduced from $28.5 million in the year-ago period.
Reduction in Force
Cibus announced a reduction in force post-quarter-end to streamline operations, expecting related one-time charges of approximately $0.5 million in the third quarter.
Company Guidance
During the Cibus Second Quarter 2025 Results Conference Call, the company provided several key metrics and guidance for their future operations. Cibus is targeting initial revenue recognition by 2026, driven by their rice herbicide tolerance traits, HT1 and HT3, which are projected to generate over $200 million in potential annual royalty revenue from target geographies in the United States and Latin America. The traits are slated for initial launches in Latin America in 2027 and the U.S. in 2028. Additionally, Cibus expects nominal revenue from their biofragrance products to begin later this year, with commercial expansion ramping up in 2026. To extend their cash runway and focus resources, the company aims to reduce annual cash usage to approximately $30 million by 2026. Their cash and cash equivalents stood at $36.5 million as of June 30, 2025, bolstered by $27.5 million from a recent public offering. The company is also seeing positive regulatory progress, which is expected to facilitate global market penetration.

Cibus Financial Statement Overview

Summary
Cibus is experiencing financial difficulties with persistent net losses and negative cash flows. Despite some revenue growth, high debt levels and negative profitability margins indicate a precarious financial position.
Income Statement
30
Negative
Cibus shows a pattern of increasing revenue in the TTM with a 11.5% growth from the previous annual period. However, the company continues to face significant challenges with profitability, as evidenced by a negative EBIT margin and net profit margin. The gross profit margin is positive, but the overall financial health is weakened by substantial net losses.
Balance Sheet
40
Negative
The company's balance sheet indicates a high debt-to-equity ratio, showing a heavy reliance on debt financing. The return on equity remains negative, reflecting ongoing net losses. However, the equity ratio is relatively stable, suggesting some level of balance sheet strength.
Cash Flow
35
Negative
Cibus has a negative free cash flow, which has deteriorated further in the TTM. The operating cash flow to net income ratio is negative, indicating operational challenges in generating cash. While financing activities provide some cash inflow, the continuous negative free cash flow poses a risk to financial sustainability.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.85M4.26M1.82M157.00K25.99M23.85M
Gross Profit4.85M4.26M1.42M-1.38M-2.57M-11.28M
EBITDA-262.49M-241.63M-314.58M-15.21M-25.43M-41.53M
Net Income-275.33M-251.39M-267.63M-16.89M-29.20M-44.84M
Balance Sheet
Total Assets346.20M350.07M544.41M22.42M37.19M63.33M
Cash, Cash Equivalents and Short-Term Investments36.46M14.43M32.70M3.43M13.82M29.00M
Total Debt35.42M36.29M24.62M13.54M17.88M19.76M
Total Liabilities271.72M252.24M206.12M15.19M23.06M26.45M
Stockholders Equity72.12M92.16M293.47M7.23M14.13M36.88M
Cash Flow
Free Cash Flow-53.74M-58.85M-50.53M-20.88M-19.31M-45.46M
Operating Cash Flow-52.95M-58.04M-46.21M-19.36M-18.81M-43.67M
Investing Cash Flow-795.00K-808.00K55.06M-1.52M11.20M-13.48M
Financing Cash Flow60.18M40.60M20.32M9.99M3.74M15.41M

Cibus Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.26
Price Trends
50DMA
1.49
Negative
100DMA
1.81
Negative
200DMA
2.29
Negative
Market Momentum
MACD
-0.07
Negative
RSI
37.51
Neutral
STOCH
41.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBUS, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.49, and below the 200-day MA of 2.29, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 37.51 is Neutral, neither overbought nor oversold. The STOCH value of 41.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CBUS.

Cibus Risk Analysis

Cibus disclosed 50 risk factors in its most recent earnings report. Cibus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cibus Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
$118.63M-90.25%-45.35%96.80%
51
Neutral
$7.91B-0.36-41.71%2.23%23.45%-1.86%
51
Neutral
21.15%46.44%
50
Neutral
$66.81M-37.45%-39.62%6.83%
46
Neutral
$62.55M-240.21%49.82%
42
Neutral
$68.36M-160.72%63.66%36.72%
37
Underperform
-17.06%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CBUS
Cibus
1.26
-3.19
-71.69%
AVTX
Avalo Therapeutics
10.16
2.60
34.39%
INZY
Inozyme Pharma
4.00
-0.98
-19.68%
KRON
Kronos Bio
0.88
-0.10
-10.20%
GANX
Gain Therapeutics
1.74
0.69
65.71%
MGX
Metagenomi, Inc.
1.78
-0.94
-34.56%

Cibus Corporate Events

Business Operations and Strategy
Cibus Announces Workforce Reduction Strategy
Negative
Jul 23, 2025

On July 21, 2025, Cibus, Inc. announced a reduction in workforce by approximately 34 full-time employees as part of its strategy to streamline business operations and focus on its most immediate and funded commercial opportunities. This move is expected to be completed by December 31, 2025, with the company incurring around $0.5 million in one-time charges for accrued vacation and severance payments in the third quarter of 2025, impacting affected employees who were informed on July 23, 2025.

Private Placements and FinancingRegulatory Filings and Compliance
Cibus Announces Public Offering of Common Stock
Neutral
Jun 6, 2025

On June 5, 2025, Cibus, Inc. entered into Securities Purchase Agreements with various investors, including its Board Chairman, as part of a public offering of 15,714,285 shares of Class A Common Stock. The offering, registered with the SEC, aims to raise funds for developing weed management traits in rice and other corporate purposes. The company has placed restrictions on stock transactions for 60 days post-offering. Additionally, Cibus engaged A.G.P./Alliance Global Partners as the sole placement agent, agreeing to a fee structure based on the proceeds from the sale of shares, with certain exclusions for the Board Chairman’s purchases.

Business Operations and StrategyRegulatory Filings and Compliance
Cibus Announces Strategic Realignment to Streamline Operations
Neutral
Jun 4, 2025

Cibus, Inc. announced a strategic realignment to streamline operations, focusing on the commercial advancement of its weed management traits in rice and partner-funded sustainable ingredient programs. The company aims to reduce its annual net cash burn to $30 million by 2026 through cost-cutting measures, including rationalizing human capital and non-core facilities. Recent regulatory approvals in the U.S., Ecuador, and India support the company’s gene editing technologies, potentially enhancing its market positioning and facilitating future partnerships. Cibus plans to launch its rice traits commercially in Latin America by 2027-2028, with further expansion planned in the U.S. and Asia.

Shareholder MeetingsBusiness Operations and Strategy
Cibus Stockholders Approve 2025 Employee Stock Plan
Positive
May 27, 2025

On May 22, 2025, Cibus, Inc.’s stockholders approved the adoption of the 2025 Employee Stock Purchase Plan (ESPP) during the company’s annual meeting. The plan, which was previously approved by the Board of Directors, includes the reservation of 326,384 shares of Class A common stock, with potential for annual increases. This approval marks a significant step in enhancing employee engagement and investment in the company, potentially impacting Cibus’s market position and stakeholder interests.

Executive/Board ChangesShareholder Meetings
Cibus Approves Key Measures at Annual Meeting
Neutral
May 23, 2025

On May 22, 2025, Cibus, Inc. held its 2025 Annual Meeting of Stockholders where 64.94% of shares were represented. During the meeting, seven directors were elected, executive compensation was approved, BDO USA, P.C.’s appointment was ratified, and the 2025 Employee Stock Purchase Plan was approved. Additionally, the issuance and repricing of certain warrants, including those held by Rory Riggs, were approved, potentially leading to a change of control under Nasdaq rules.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 20, 2025